Partnering

Partnerships are a key component of Pathway’s corporate strategy to maximize the potential of its selective PI3K inhibitor platform. Pathway brings to its collaborations world class chemistry, drug discovery and development expertise. With in-house chemistry and in vitro biology capabilities and an established network of US and ex-US contract organizations, Pathway is open to a broad range of collaboration structures across both oncology and inflammation therapeutic applications. Partnering inquiries may be directed to info@pathwaytx.com